ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and pr
… a public offering in October that will allow us to fund operations into 2022, well beyond the expected top-line … of $5.50 per share with full exercise of underwriters’ option to purchase 1,363,636 additional ordinary shares. Net … financial statements, the potential exercise of share options is not included in the diluted earnings per share …
… robust clinical proof of concept in the early phase of our development program. I also want to thank the patients that … LCA10 compound heterozygous patient cells and homozygous optic cups in a dose dependent manner. Based on this data, … into pre-clinical development for the treatment of dystrophic epidermolysis bullosa (DEB). QR-313 is an RNA …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …